...
首页> 外文期刊>Blood: The Journal of the American Society of Hematology >JAK2(ex13InDel) drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera
【24h】

JAK2(ex13InDel) drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera

机译:JAK2(EX13INDEL)驱动致癌转化,与慢性嗜酸性白血病和多胆症VERA相关

获取原文
获取原文并翻译 | 示例

摘要

The V617F mutation in the JH2 domain of Janus kinase 2 (JAK2) is an oncogenic driver in several myeloproliferative neoplasms (MPNs), including essential thrombocythemia, myelofibrosis, and polycythemia vera (PV). Other mutations in JAK2 have been identified in MPNs, most notably exon 12 mutations in PV. Here, we describe a novel recurrent mutation characterized by a common 4-amino-acid deletion and variable 1-amino-acid insertion (Leu583-Ala586DellnsSer/Gln/Pro) within the JH2 domain of JAK2. All 4 affected patients had eosinophilia, and both patients with Leu583-Ala586DellnsSer fulfilled diagnostic criteria of both PV and chronic eosinophilic leukemia (CEL). Computational and functional studies revealed that Leu583-Ala586DellnsSer (herein referred to as JAK2(ex13InDel)) deregulates JAK2 through a mechanism similar to JAK2(v)(617F), activates signal transducer and activator of transcription 5 and extracellular signal-regulated kinase, and transforms parental Ba/F3 cells to growth factor independence. In contrast to JAK2(v)(617F), JAK2(ex13InDel) does not require an exogenous homodimeric type 1 cytokine receptor to transform Ba/F3 cells and is capable of activating beta common chain family cytokine receptor (interleukin-3 receptor [IL-3R], IL-5R, and granulocyte-macrophage colony stimulating factor receptor) signaling in the absence of ligand, with the maximum effect observed for IL 5R, consistent with the clinical phenotype of eosinophilia. Recognizing this new PV/CEL-overlap MPN has significant clinical implications, as both PV and CEL patients are at high risk for thrombosis, and concomitant cytoreduction of red cells, neutrophils, and eosinophils may be required for prevention of thromboembolic events. Targeted next-generation sequencing for genes recurrently mutated in myeloid malignancies in patients with unexplained eosinophilia may reveal additional cases of Leu583-Ala586DellnsSer/Gln/Pro, allowing for complete characterization of this unique MPN.
机译:Janus激酶2(JAK2)的JH2结构域(JAK2)中的V617F突变是一种致癌钳,包括几种肌酚糖类肿瘤(MPN),包括基本血小板血症,骨髓纤维化和多胆血症Vera(PV)。 JAK2中的其他突变已在MPNS中鉴定,最显着的是PV中的12个突变。在此,我们描述了一种新的复发性突变,其特征在于JAK2的JH2结构域内的共同的4-氨基酸缺失和可变的1-氨基酸插入(Leu583-Ala586dellnsssssssssssser / gln / gln / gln / gln / gln / gln / gln / gln / gln / gln / gln / gln / gln / pro)。所有4名受影响的患者都有嗜酸性粒细胞,也有leu583-ALA586DELLSSER的患者满足PV和慢性嗜酸性白血病(CEL)的诊断标准。计算和功能研究表明,Leu583-Ala586dellnsser(此处称为JAK2(EX13Indel))通过类似于JAK2(V)(617F)的机制,激活转录5和细胞外信号调节激酶的信号传感器和活化剂,以及将父母BA / F3细胞转化为生长因子独立性。与JAK2(V)(617F)相比,JAK2(EX13Indel)不需要外源同源二聚体类型1细胞因子受体来转化Ba / F3细胞,并且能够激活β常见链族细胞因子受体(白细胞介素-3受体[IL-在不存在配体的情况下,IL-5R和粒细胞 - 巨噬细胞群刺激因子受体的信号传导,与IL 5R观察到的最大效果,与嗜酸性粒细胞的临床表型一致。识别出这种新的PV / CEL - 重叠MPN具有显着的临床意义,因为PV和CEL患者血栓形成的高风险,并且可以伴随着红细胞,中性粒细胞和嗜酸性粒细胞的细胞渗透量来预防血栓栓塞事件。针对基因的靶向的下一代测序在未解释的嗜酸性粒细胞症患者中,在骨髓内核病患者中均致突变,可能揭示额外的LEU583-ALA586DELLSSER / GLN / PRO,允许完全表征这种独特的MPN。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号